Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies

Overview of attention for article published in The Journal of Headache and Pain, December 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 14 X posts from 13 X users, with an upper bound of 22,471 followers.

RT @EHF_Official: Discontinuation of #CGRP (receptor)monoclonal antibodies led to deterioration of quality of life in #migraine patients. M…

RT @williambyoung59: Listen up @ibx @UnitedHealthGrp @humana @Cigna @Aetna @AnthemBCBS Your shenanigans harm MY patients (and everyone els…

RT @EHF_Official: Discontinuation of #CGRP (receptor)monoclonal antibodies led to deterioration of quality of life in #migraine patients. M…

RT @EHF_Official: Discontinuation of #CGRP (receptor)monoclonal antibodies led to deterioration of quality of life in #migraine patients. M…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.